In the current era of lung cancer diagnosis and management, increasingly featuring more immunotherapy and requiring molecular profiling, pathologists face new challenges. Here, Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, UK, discusses this changing field, and addresses the importance of the quality and quantity of samples. This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference in Dublin, Ireland.

свернуть